title: [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
abstract: We report a case of a patient with lung adenocarcinoma and bone and extraosseus metastases studied with (18)F-FDG PET-CT, (99m)Tc-HMDP and (18)F-fluoride PET-CT. It assesses the usefulness of (18)F-FDG PET-CT for initial staging of the disease and monitoring response to therapy. For the study of the sclerotic bone metastases it shows the superiority of 99mTc-HMDP bone scintigraphy and (18)F-fluoride PET-CT over (18)F-FDG PET-CT, and (18)F-fluoride PET-CT over bone scintigraphy. It also shows the usefulness of (18)F-fluoride PET-CT for monitoring the bone metastases.
authors.affiliation: Unitat PET Esplugues de Llobregat, CETIR-ERESA Grup Mèdic, Barcelona, España. Electronic address: mmoragas@cetir.es.
authors.forename: M
authors.initials: M
authors.lastname: Moragas
authors.affiliation: Unitat PET Esplugues de Llobregat, CETIR-ERESA Grup Mèdic, Barcelona, España.
authors.forename: M
authors.initials: M
authors.lastname: Soler
authors.affiliation: Unitat PET Esplugues de Llobregat, CETIR-ERESA Grup Mèdic, Barcelona, España.
authors.forename: E
authors.initials: E
authors.lastname: Riera
authors.affiliation: Unitat PET Esplugues de Llobregat, CETIR-ERESA Grup Mèdic, Barcelona, España.
authors.forename: J R
authors.initials: JR
authors.lastname: García
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary; D016190:Carboplatin / Q000008:administration & dosage; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D005459:Fluorides / Q000008:administration & dosage; D005462:Fluorine Radioisotopes / Q000008:administration & dosage; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009367:Neoplasm Staging; D010026:Osteosclerosis / Q000000981:diagnostic imaging / Q000209:etiology; D017239:Paclitaxel / Q000008:administration & dosage; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011799:Quinazolines / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D013365:Submandibular Gland Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary; D013669:Technetium Tc 99m Medronate / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D005462:Fluorine Radioisotopes; D009363:Neoplasm Proteins; D011799:Quinazolines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D016190:Carboplatin; C512478:EGFR protein, human; D066246:ErbB Receptors; D017239:Paclitaxel; D005459:Fluorides; D000077156:Gefitinib; D013669:Technetium Tc 99m Medronate
keywords: 18F-FDG positron emission tomography-computed tomography; 18F-Fluoride positron emission tomography-computed tomography; Adenocarcinoma de pulmón; Bone metastases; Lung adenocarcinoma; Metástasis óseas; Tomografía por emisión de positrones-tomografía computarizada con 18F-FDG; Tomografía por emisión de positrones-tomografía computarizada con 18F-Fluroruro